D Scarnecchia

Member, Data Science and Ethics Group (a nascent inter-agency working group focused on the risks posed to displaced persons by advanced data science, machine learning, and artificial intelligence) - Ethics Reviewer, Humanitarian Data Science Review - Freelance cartographic, network, and data visualizations for political risk clientele

Researched governance and management issues related to the use of ICTs and information in humanitarian response with a particular focus on standards and ethics, and the impact of technology on humanitarian crises and affected populations. - Investigated the safe, ethical, and rights-based use of digital ICTs and data in humanitarian settings through scholarly research and field assessments: - Co-authored a rights-based approach for assessing digital technology and data use during humanitarian crises, as well as the subsequent obligations necessary for humanitarian agencies to realize these rights - Developed an assessment template and capacity development curriculum to help organizations understand the scope of the digital technology use and associated risks - Created and facilitated workshops on the use of digital information and communication technologies for humanitarian practitioners - Engaged with internal and external stakeholders to support the Signal Program’s research aims: - Collaborated across institutions to help produce interdisciplinary work on topics ranging from GDPR compliance to the impact of disinformation on the Syria conflict - Facilitated workshops and panels on future technological threats to the humanitarian system - Promoted the Signal Program’s research through digital outreach, public speaking, and written communications - Designed promotional materials, including posters for speaking engagements and event invitations, as well as document layout for research reports - Held Signal Program corporate card, made team travel arrangements, and managed reimbursements per University guidelines

Developed strategies with pharmaceutical industry clients for the generation of real-world evidence for drug safety surveillance and health economics and outcomes research - Wrote landscape reports monitoring policy changes and industry trends and assessed the business impacts and opportunities of emerging technologies - Designed research frameworks, governance policies, and procedures for the creation of multi-stakeholder distributed research networks using real-world evidence to monitor drug safety and effectiveness - Convened industry, healthcare, academia, and government actors to build organizations which met the varied regulatory and business needs of stakeholders, including: • the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), a $8M, multi-stakeholder distributed research network to monitor the safety and effectiveness of biologics and biosimilars • a three-year, $18M research plan for the Observational Medical Outcomes Partnership (OMOP) drug safety methods public private partnership